Mirxes Holding Co., Ltd. operates as an investment holding company. The company employs 347 full-time employees The company went IPO on 2025-05-23. The company develops and commercializes accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Its segments include Infectious diseases and Early detection and precision multi-omics. Its solutions include cancer screening; clinical sequencing; cancer treatment selection, and infectious diseases. Its core product (namely, GASTROClear), two other commercialized products (namely, LUNGClear and Fortitude), and six product candidates at pre-clinical stage. GASTROClear is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. LUNGClear, its lung cancer screening product candidate, is a detection panel consisting of miRNA biomarkers discovered and verified in multi-center studies. The company offers complete COVID-19 testing solutions.
02629.HK stock price ended at $42.24 on 星期一, after rising 1.78%
On the latest trading day Jan 19, 2026, the stock price of 02629.HK rose by 1.78%, climbing from $41.50 to $42.24. During the session, the stock saw a volatility of 4.82%, with prices oscillating between a daily low of $41.46 and a high of $43.46. Notably, trading volume dropped by 4.9K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 455.3K shares were traded, equating to a market value of approximately $11.6B.